Brustzentrum
  1. Startseite LMU Klinikum
  2. Brustzentrum
  3. Aktuelles
  4. Newsmeldungen
  5. Archivierte Newsmeldungen
  6. Nadia Harbeck spricht über Studie DESTINY-Breast11
News | 10.12.2021
KONGRESSBERICHT SAN ANTONIO BREAST CANCER SYMPOSIUM 2021

Nadia Harbeck spricht über Studie DESTINY-Breast11

Nadia Harbeck, MD, PhD, speaks about open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)

Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany speaks about the SABCS Abstract - OT1-12-04 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11).